Effect of Enalaprilat on nitric oxide activity in coronary artery disease

Abhiram Prasad, Syed Husain, Arshed A. Quyyumi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Atherosclerosis is associated with vascular endothelial dysfunction and reduced nitric oxide (NO) activity. Enhancement of NO activity may have an antiatherogenic action. This study was performed to determine whether angiotensin-converting enzyme (ACE) inhibition improves peripheral vascular NO activity in patients with atherosclerosis. In the femoral circulation of 43 patients with atherosclerosis and 10 controls, we studied endothelium- dependent vasedilation with bradykinin and acetylcholine, and endothelium- independent vasodilation with sodium nitroprusside before and after enalaprilat. In 22 patients, we repeated these infusions in the presence of L-N(G) monomethyl arginine (L-NMMA). Doppler-femoral artery flow velocity was measured. Before ACE inhibition, acetylcholine responses were depressed in patients with atherosclerosis compared with controls (p = 0.03). Enalaprilat did not alter femoral vascular tone at rest or vasodilation with sodium nitroprusside, but potentiated bradykinin-mediated vasodilation in patients (p <0.001) and controls (p = 0.02). Acetylcholinemediated vasodilation was augmented only in patients (p <0.001), but not in control subjects. L-NMMA inhibited the potentiation by enalaprilat of acetylcholine and bradykinin responses. This study demonstrates that ACE inhibition selectively improves endothelial dysfunction in human atherosclerosis by enhancing NO activity. The antithrombotic and antiproliferative effects of NO may reduce adverse manifestations related to atherosclerosis during long-term therapy.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalAmerican Journal of Cardiology
Volume84
Issue number1
StatePublished - Jul 1 1999
Externally publishedYes

Fingerprint

Enalaprilat
Coronary Artery Disease
Atherosclerosis
Nitric Oxide
Vasodilation
Bradykinin
Peptidyl-Dipeptidase A
Acetylcholine
Blood Vessels
Nitroprusside
Thigh
Endothelium
Arginine
Femoral Artery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of Enalaprilat on nitric oxide activity in coronary artery disease. / Prasad, Abhiram; Husain, Syed; Quyyumi, Arshed A.

In: American Journal of Cardiology, Vol. 84, No. 1, 01.07.1999, p. 1-6.

Research output: Contribution to journalArticle

Prasad, A, Husain, S & Quyyumi, AA 1999, 'Effect of Enalaprilat on nitric oxide activity in coronary artery disease', American Journal of Cardiology, vol. 84, no. 1, pp. 1-6.
Prasad, Abhiram ; Husain, Syed ; Quyyumi, Arshed A. / Effect of Enalaprilat on nitric oxide activity in coronary artery disease. In: American Journal of Cardiology. 1999 ; Vol. 84, No. 1. pp. 1-6.
@article{674f95d247894201b2a814867397d022,
title = "Effect of Enalaprilat on nitric oxide activity in coronary artery disease",
abstract = "Atherosclerosis is associated with vascular endothelial dysfunction and reduced nitric oxide (NO) activity. Enhancement of NO activity may have an antiatherogenic action. This study was performed to determine whether angiotensin-converting enzyme (ACE) inhibition improves peripheral vascular NO activity in patients with atherosclerosis. In the femoral circulation of 43 patients with atherosclerosis and 10 controls, we studied endothelium- dependent vasedilation with bradykinin and acetylcholine, and endothelium- independent vasodilation with sodium nitroprusside before and after enalaprilat. In 22 patients, we repeated these infusions in the presence of L-N(G) monomethyl arginine (L-NMMA). Doppler-femoral artery flow velocity was measured. Before ACE inhibition, acetylcholine responses were depressed in patients with atherosclerosis compared with controls (p = 0.03). Enalaprilat did not alter femoral vascular tone at rest or vasodilation with sodium nitroprusside, but potentiated bradykinin-mediated vasodilation in patients (p <0.001) and controls (p = 0.02). Acetylcholinemediated vasodilation was augmented only in patients (p <0.001), but not in control subjects. L-NMMA inhibited the potentiation by enalaprilat of acetylcholine and bradykinin responses. This study demonstrates that ACE inhibition selectively improves endothelial dysfunction in human atherosclerosis by enhancing NO activity. The antithrombotic and antiproliferative effects of NO may reduce adverse manifestations related to atherosclerosis during long-term therapy.",
author = "Abhiram Prasad and Syed Husain and Quyyumi, {Arshed A.}",
year = "1999",
month = "7",
day = "1",
language = "English (US)",
volume = "84",
pages = "1--6",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effect of Enalaprilat on nitric oxide activity in coronary artery disease

AU - Prasad, Abhiram

AU - Husain, Syed

AU - Quyyumi, Arshed A.

PY - 1999/7/1

Y1 - 1999/7/1

N2 - Atherosclerosis is associated with vascular endothelial dysfunction and reduced nitric oxide (NO) activity. Enhancement of NO activity may have an antiatherogenic action. This study was performed to determine whether angiotensin-converting enzyme (ACE) inhibition improves peripheral vascular NO activity in patients with atherosclerosis. In the femoral circulation of 43 patients with atherosclerosis and 10 controls, we studied endothelium- dependent vasedilation with bradykinin and acetylcholine, and endothelium- independent vasodilation with sodium nitroprusside before and after enalaprilat. In 22 patients, we repeated these infusions in the presence of L-N(G) monomethyl arginine (L-NMMA). Doppler-femoral artery flow velocity was measured. Before ACE inhibition, acetylcholine responses were depressed in patients with atherosclerosis compared with controls (p = 0.03). Enalaprilat did not alter femoral vascular tone at rest or vasodilation with sodium nitroprusside, but potentiated bradykinin-mediated vasodilation in patients (p <0.001) and controls (p = 0.02). Acetylcholinemediated vasodilation was augmented only in patients (p <0.001), but not in control subjects. L-NMMA inhibited the potentiation by enalaprilat of acetylcholine and bradykinin responses. This study demonstrates that ACE inhibition selectively improves endothelial dysfunction in human atherosclerosis by enhancing NO activity. The antithrombotic and antiproliferative effects of NO may reduce adverse manifestations related to atherosclerosis during long-term therapy.

AB - Atherosclerosis is associated with vascular endothelial dysfunction and reduced nitric oxide (NO) activity. Enhancement of NO activity may have an antiatherogenic action. This study was performed to determine whether angiotensin-converting enzyme (ACE) inhibition improves peripheral vascular NO activity in patients with atherosclerosis. In the femoral circulation of 43 patients with atherosclerosis and 10 controls, we studied endothelium- dependent vasedilation with bradykinin and acetylcholine, and endothelium- independent vasodilation with sodium nitroprusside before and after enalaprilat. In 22 patients, we repeated these infusions in the presence of L-N(G) monomethyl arginine (L-NMMA). Doppler-femoral artery flow velocity was measured. Before ACE inhibition, acetylcholine responses were depressed in patients with atherosclerosis compared with controls (p = 0.03). Enalaprilat did not alter femoral vascular tone at rest or vasodilation with sodium nitroprusside, but potentiated bradykinin-mediated vasodilation in patients (p <0.001) and controls (p = 0.02). Acetylcholinemediated vasodilation was augmented only in patients (p <0.001), but not in control subjects. L-NMMA inhibited the potentiation by enalaprilat of acetylcholine and bradykinin responses. This study demonstrates that ACE inhibition selectively improves endothelial dysfunction in human atherosclerosis by enhancing NO activity. The antithrombotic and antiproliferative effects of NO may reduce adverse manifestations related to atherosclerosis during long-term therapy.

UR - http://www.scopus.com/inward/record.url?scp=0033024364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033024364&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 1

EP - 6

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -